PE-22-28 is a synthetic derivative of spadin of a naturally occurring peptide spadin. This chemical binds to TREK-1. TREK-1, commonly found in the brain, may even be present in the heart, smooth muscle tissue, lungs, the prostate, and certain parts of the pancreas. TREK-1 is typically located in brain-controlling mood regions.
PE-22-28 is being studied for its ability to address mental health. This synthetic chemical compound may provide antidepressant activity, learning, and stroke recovery. Small-scale studies even suggest that PE-22-28 could be a future treatment for neurodegenerative diseases like Alzheimer’s.
Because PE-22-28 is an experimental peptide, it is unsafe for human consumption. Buy PE-22-28 for research purposes only.
The synthetic protein PE-22-28 is a derivative of the naturally occurring protein spadin.
It is a TREK-1 receptor antagonist, a two-pore potassium channel identified as a potential target in the therapy of depression, and a potential neurogenic regulator. TREK-1 receptor deletion makes mice immune to depression, according to preliminary research. Similarly, sortilin therapy increases resilience to depression and increases the development of neurons as well as synaptic linkages between neurons.
Even more, mice treated with PE-22-28 are allegedly capable of demonstrating more resistance against developing generalized seizures. This particular aspect of PE-22-28 makes it a potential peptide for speeding up neurogenesis in the hippocampus.
Sortilin, a protein abundant in the body’s central nervous system, is the source of the natural peptide known as spadin. Spadin itself is less effective than shorter analogous versions in treating depression. One such shortened peptide derivative of this protein is known as PE-22-28, which, like spadin, is known to act on the TREK-1 receptor to produce its effects.